Business
AtriCure Announces Proposed Public Offering of Common Stock
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage
About this update from Atricure, Inc.
[{"type":"text","content":" MASON, Ohio--(BUSINESS WIRE)--\nAtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its existing automatic shelf registration statement. In connection with this offering, AtriCure plans to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price less the underwriting discounts and commissions. AtriCure intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include repayment of debt or long-term liabilities, and other potential corporate or market development activities.\n\n\nJ.P. Morgan and Piper Sandler are acting as joint book-running managers for the offering. Canaccord Genuity, Needham & Company, Stifel, SVB Leerink and BTIG are acting as co-managers. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.\n\n\nThe securities described above are being offered by AtriCure pursuant to an automatic shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on March 1, 2019. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [email protected].\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities...